AZNCF News and Press, AstraZeneca Plc From 12/21/20

Novavax's COVID-19 vaccine has shown efficacy in clinical trials. Late-stage trials could commence within days. NVAX's vaccine can be stored at refrigerated temperatures. Mass doses could potentially be easier to distribute vis-a-vis PFE or MRNA. The stock trades at 2x projected 2...

AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call December 12, 2020 09:00 AM ET Company Participants Nick Stone - IR, AstraZeneca Pascal Soriot - CEO, AstraZeneca Marc Dunoyer - CFO, AstraZeneca Mene Pangalos - EVP of BioPharmaceuticals R&D, AstraZeneca Ludwig Hantson -...

AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential. AstraZeneca is working to position itself...

Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V. Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac....

All four major U.S. equity indexes closed this past week at fresh record highs on signs of progress on stalled stimulus talks and the first regulatory approval of a coronavirus vaccine. Having now rebounded by over 65% from its pandemic lows, the S&P 500 rallied another 1.7% this ...

UK government scoops the US in authorizing the use of the Pfizer/BioNTech vaccine; roll out to commence next week. FDA and EU approval probably not far off. The Pfizer/BioNTech vaccine has first mover advantage. BioNTech stock could experience further gains at least in the short term....

Silverback Therapeutics has filed proposed terms for its $125 million IPO. The firm is advancing programs to treat various highly prevalent forms of cancer. SBTX has produced initially intriguing results but investors will likely need to wait until 2022 to see a meaningful catalys...

Up until recently, dividend stock performance has been a mixed bag with high yielders being notable underachievers. A COVID vaccine-inspired economic recovery in 2021 could put value stocks, dividend payers and cyclicals back into market leadership positions. PEY is well-positione...

Most investors are focused on the bad news affecting REITs. But there has been a lot of very good news lately. We discuss where we find the best opportunities in today's market. For further details see: Very Good News For REITs

Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...